Revelation Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.1M
- Price
- $0.7895
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.96%
- Volume
- 9.4K
About
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Quick stats
Shares outstanding4.0M
Computed float3.4M
Float / shares85.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001810560
AI Summary
AI-generated1/8
standardbullishclinical trial
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 adaptive-design TITAN study.
The trial will evaluate the company's proprietary formulation, Gemini, as a treatment for patients with acute kidney injury.
Management confirmed that the study is on track to begin later this year, marking a significant advancement in the company's clinical pipeline.